Literature DB >> 9673361

The prognostic value of alpha-thymosins in breast cancer.

O E Tsitsilonis1, E Bekris, I F Voutsas, C N Baxevanis, C Markopoulos, S A Papadopoulou, K Kontzoglou, S Stoeva, J Gogas, W Voelter, M Papamichail.   

Abstract

The prognosis of breast cancer is of major clinical importance and several histopathological, biochemical and immunological variables have been reported to be useful prognostic factors. In the present study, we investigated the clinical significance of the levels of alpha-thymosins in relation to established prognostic factors, both in breast cancer and non-malignant breast lesions, alpha-thymosin levels were measured in breast tissue extracts by specific radioimmunoassays (RIAs) developed for human prothymosin alpha (ProT alpha) and parathymosin alpha (ParaT alpha) and were found to be significantly higher (up to 17.2-fold) in malignant but not in benign breast lesions, as compared to the values of the neighbouring tissues. When alpha-thymosin levels of the tumor samples were correlated with various known prognostic parameters a statistically significant correlation (p < 0.05) was observed between the levels of ProT alpha in malignant tissues to the grade of cancer and the lymph node status of the patient. An association between ProT alpha levels with increase in risk of death from breast cancer was also noticed. These results suggest that the expression of alpha-thymosins in human breast cancer a) depends on the proliferation status of the tumor, b) associates with established prognostic factors describing the metastatic potential of the tumor and c) is related to the overall survival of the patient. The fact that such relationships hold only for cancer tissues encourages the future use of alpha-thymosins as potent prognostic factors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673361

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity.

Authors:  P G Martini; R Delage-Mourroux; D M Kraichely; B S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Identification of common microRNA-mRNA regulatory biomodules in human epithelial cancers.

Authors:  Xinan Yang; Younghee Lee; Hong Fan; Xiao Sun; Yves A Lussier
Journal:  Chin Sci Bull       Date:  2010-11

Review 3.  Breast cancer proteomics: a review for clinicians.

Authors:  E R C G N Galvão; L M S Martins; J O Ibiapina; H M Andrade; S J H Monte
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-05       Impact factor: 4.553

Review 4.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

5.  Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy.

Authors:  Eiki Ojima; Yasuhiro Inoue; Chikao Miki; Masaki Mori; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

6.  Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer.

Authors:  C Magdalena; F Dominguez; L Loidi; J L Puente
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 7.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.